Cited 1 times in
Acute toxicity of cyclooxygenase-2 inhibitor rofecoxib as a radiosensitizer for concurrent chemoradiation in the treatment of uterine cervical cance
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김상운 | - |
dc.contributor.author | 김영태 | - |
dc.contributor.author | 김재욱 | - |
dc.contributor.author | 김재훈 | - |
dc.contributor.author | 남은지 | - |
dc.contributor.author | 백지흠 | - |
dc.contributor.author | 이산희 | - |
dc.contributor.author | 정용욱 | - |
dc.date.accessioned | 2015-04-24T17:11:50Z | - |
dc.date.available | 2015-04-24T17:11:50Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 2005-0380 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/104938 | - |
dc.description.abstract | OBJECTIVE: To evaluate the acute toxicity of rofecoxib during concurrent use with cisplatin-based chemoradiotherapy (CCRT) in patients with cervical cancer. METHODS: We evaluated 67 FIGO stage IB2-IVA cervical cancer patients treated with CCRT between June 2002 and July 2004. The study group included patients who received rofecoxib (N=30) and the control group included patients who received CCRT only (N=37). The patients' medical records were retrospectively reviewed for patient characteristics, toxicity related to CCRT and treatment results. RESULTS: There were no significant differences in toxicity between the two groups. The most common acute grade 3/4 toxicity was neutropenia (13.3% in the study group and 21.6% in the control group). Grade 3/4 late toxicity was observed in 2 (6.6%) patients in the study group and 3 (8.1%) in the control group. There was no treatment-related deaths in either group. Six (20.0%) patients in the study group had treatment failure. In the control group, 6 (16.2%) patients experienced treatment failure. Progression-free and overall survival was 55.8+/-4.2 and 59.0+/-2.8 months, respectively, in the study group, and 69.7+/-4.3 and 71.6+/-3.6 months, respectively, in the control group. There were no differences in progression-free and overall survival between the 2 groups. CONCLUSION: Our data indicate that rofecoxib, at a dose of 25 mg twice daily, has acceptable acute toxicity as a radiosensitizer during CCRT. Although rofecoxib was not efficacious as a radiosensitizer in the present study, the benefit of rofecoxib as a radiosensitizer should be further evaluated in a prospective study. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 151~157 | - |
dc.relation.isPartOf | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Acute toxicity of cyclooxygenase-2 inhibitor rofecoxib as a radiosensitizer for concurrent chemoradiation in the treatment of uterine cervical cance | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Obstetrics & Gynecology (산부인과학) | - |
dc.contributor.googleauthor | Yong Wook Jung | - |
dc.contributor.googleauthor | San Hui Lee | - |
dc.contributor.googleauthor | Ji Heum Paek | - |
dc.contributor.googleauthor | Eun Ji Nam | - |
dc.contributor.googleauthor | Sang Wun Kim | - |
dc.contributor.googleauthor | Jae Hoon Kim | - |
dc.contributor.googleauthor | Jae Wook Kim | - |
dc.contributor.googleauthor | Young Tae Kim | - |
dc.identifier.doi | 10.3802/jgo.2009.20.3.151 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00526 | - |
dc.contributor.localId | A00729 | - |
dc.contributor.localId | A00876 | - |
dc.contributor.localId | A01262 | - |
dc.contributor.localId | A01840 | - |
dc.contributor.localId | A02808 | - |
dc.contributor.localId | A03661 | - |
dc.contributor.localId | A00866 | - |
dc.relation.journalcode | J01428 | - |
dc.identifier.eissn | 2005-0399 | - |
dc.identifier.pmid | 19809548 | - |
dc.subject.keyword | Cervical cancer | - |
dc.subject.keyword | Chemoradiotherapy | - |
dc.subject.keyword | Efficacy | - |
dc.subject.keyword | Rofecoxib | - |
dc.subject.keyword | Toxicity | - |
dc.contributor.alternativeName | Kim, Sang Wun | - |
dc.contributor.alternativeName | Kim, Young Tae | - |
dc.contributor.alternativeName | Kim, Jae Wook | - |
dc.contributor.alternativeName | Kim, Jae Hoon | - |
dc.contributor.alternativeName | Nam, Eun Ji | - |
dc.contributor.alternativeName | Paek, Ji Heum | - |
dc.contributor.alternativeName | Lee, San Hui | - |
dc.contributor.alternativeName | Jung, Yong Wook | - |
dc.contributor.affiliatedAuthor | Kim, Sang Wun | - |
dc.contributor.affiliatedAuthor | Kim, Young Tae | - |
dc.contributor.affiliatedAuthor | Kim, Jae Hoon | - |
dc.contributor.affiliatedAuthor | Nam, Eun Ji | - |
dc.contributor.affiliatedAuthor | Paek, Ji Heum | - |
dc.contributor.affiliatedAuthor | Lee, San Hui | - |
dc.contributor.affiliatedAuthor | Jung, Yong Wook | - |
dc.contributor.affiliatedAuthor | Kim, Jae Wook | - |
dc.citation.volume | 20 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 151 | - |
dc.citation.endPage | 157 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GYNECOLOGIC ONCOLOGY, Vol.20(3) : 151-157, 2009 | - |
dc.identifier.rimsid | 54679 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.